Toggle light / dark theme

KENNEDY SPACE CENTER (FL), October 19, 2020 – The Center for the Advancement of Science in Space (CASIS) and the National Science Foundation (NSF) announced three flight projects that were selected as part of a joint solicitation focused on leveraging the International Space Station (ISS) U.S. National Laboratory to further knowledge in the fields of tissue engineering and mechanobiology. Through this collaboration, CASIS, manager of the ISS National Lab, will facilitate hardware implementation, in-orbit access, and astronaut crew time on the orbiting laboratory. NSF invested $1.2 million in the selected projects, which are seeking to advance fundamental science and engineering knowledge for the benefit of life on Earth.

This is the third collaborative research opportunity between CASIS and NSF focused on tissue engineering. Fundamental science is a major line of business for the ISS National Lab, and by conducting research in the persistent microgravity environment offered by the orbiting laboratory, NSF and the ISS National Lab will drive new advances that will bring value to our nation and spur future inquiries in low Earth orbit.

Microgravity affects organisms—from viruses and bacteria to humans, inducing changes such as altered gene expression and DNA regulation, changes in cellular function and physiology, and 3D aggregation of cells. Spaceflight is advancing research in the fields of pharmaceutical research, disease modeling, regenerative medicine, and many other areas within the life sciences. The selected projects will utilize the ISS National Lab and its unique environment to advance fundamental and transformative research that integrates engineering and life sciences.

Dr. Adam Freund PhD., Calico Life Sciences, Discussing Google Quest to Solve Aging.


Ira Pastor, ideaXme life sciences ambassador interviews Dr Adam Freund, PhD, Principal Investigator at Calico Life Sciences (Calico). https://www.calicolabs.com

Ira Pastor comments:

Calico is a research and development focused biotechnology company founded and backed by Google / Alphabet with the goal of combating aging and associated age-related diseases.

Calico has a billion dollar partnership with the bio-pharma giant AbbVie, focused on aging and age-related diseases, such as neuro-degeneration and cancer. Calico also has partnerships with the University of Texas Southwestern Medical Center and 2M Companies (regarding drug development for neurodegenerative disorders), the Broad Institute of MIT and Harvard (to advance research on age-related diseases and therapeutics), and a partnership with the Buck Institute for Research on Aging.

Calico has also announced a partnership with the California Institute for Quantitative Biosciences (QB3) based on researching the biology of aging and identifying potential therapeutics for age-related diseases, as well as and one with Ancestry-DNA based on conducting research into the genetics of human lifespan.

Dr. Adam Freund, Ph.D., is a Principal Investigator at Calico Life Sciences studying aging on the systems biology level.

With a Ph.D. in Molecular and Cell Biology, from the University of California at Berkeley, and a B.S. in Materials Science and Engineering from Stanford University, Dr. Freund’s lab works to identify and test post-developmental interventions that slow or reverse aspects of aging, as well as understand whether aging is regulated by similar mechanisms in diverse tissue compartments. To accomplish these goals, his lab develops automated, high content methods to quantify longitudinal decline and build tools to modulate targets with spatial and temporal precision in preclinical models, including gene delivery as well as small and large molecules. They use these tools to test hypotheses of aging in rapid, functionally relevant ways.

Can sub-zero stasis help humans escape death? In episode five of Hacking the Apocalypse, Claire Reilly goes inside a cryonics facility to investigate the experimental search for a second life.

CNET playlists: https://www.youtube.com/user/CNETTV/playlists
Download the new CNET app: https://cnet.app.link/GWuXq8ExzG
Like us on Facebook: https://www.facebook.com/cnet
Follow us on Twitter: https://www.twitter.com/cnet
Follow us on Instagram: http://bit.ly/2icCYYm

CJD happens when proteins called prions, which form incorrectly, find their way into the brain. Prions have the unfortunate, destructive ability to deform the proteins around them as well. As the prions gradually eat away at neurons, they create sponge-like holes in the brain. This leads to dementia, loss of bodily function, and eventually coma and death.

A new study — published last month in the journal Scientific Reports — looked at national data on people 50 years and older from Japan between the years 2005 and 2014 and found a gradual rise in the country’s CJD cases and deaths. The increase in both was most prominent among those older 70, but the Okayama University scientists behind the research saw a rise of CJD even after the data had been corrected for age.

“Given this trend in aging of population, the disease burden of CJD will continue to increase in severity,” the scientists wrote in their paper. “Our findings thus recommend that policymakers be aware of the importance of CJD and focus on preparing to address the increasing prevalence of dementia.”

A gene therapy that could restore the fading sight of the elderly is being tested on humans for the first time after positive results in blind mice.

It could be used to treat age-related macular degeneration, a common condition that usually first affects people in their 50s and 60s, scientists said.

It involves a one-time injection of a modified virus into the eye. This viral vector is altered to contain a synthetic gene that produces a protein that plays a critical role in the perception of light.

Though its a bit old, and sometimes innacurate or snarky in narration, it’s still the most detailed depiction of the cryonics process — the procedure itself on a real person, the person preserved before dying and her family as they decide to do this, deal with her death, and reflect on it after she’s preserved. It’s quite emotional and sometimes graphic, but well worth watching. Will it work? Maybe. But if you are NOT preserved there is NO chance at all. From your perspective it’d be like waking up right after dying in some distant future without feeling like any time passed at all.

That sounds a hell of a lot more appealing and likely than a bearded man on a fluffy cloud winking at me after I die.


Anita Riskin is one of hundreds of people who believe in cryonics — the process where doctors freeze human bodies. Preserve them, so that some time in the future they can be resuscitated — brought back to life. Now, as Anita Riskin sets out on her amazing journey, for the first time, you’ll see how it’s actually done — at times, quite graphically.

For forty years, 60 Minutes have been telling Australians the world’s greatest stories. Tales that changed history, our nation and our lives. Reporters Liz Hayes, Allison Langdon, Tara Brown, Charles Wooley, Liam Bartlett and Tom Steinfort look past the headlines because there is always a bigger picture. Sundays are for 60 Minutes.

WATCH more of 60 Minutes Australia: https://www.60minutes.com.au
LIKE 60 Minutes Australia on Facebook: https://www.facebook.com/60Minutes9
FOLLOW 60 Minutes Australia on Twitter: https://twitter.com/60Mins
FOLLOW 60 Minutes Australia on Instagram: https://www.instagram.com/60minutes9

The researchers found that while equol production did not appear to impact levels of amyloid-beta deposited within the brain, it was associated with reduced white matter lesion volumes. Sekikawa’s team also discovered that high levels of isoflavones—soy nutrients that are metabolized into equol—had no effect on levels of white matter lesions or amyloid-beta when equol wasn’t produced.

According to Sekikawa, the ability to produce equol from soy isoflavones may be the key to unlocking protective health benefits from a soy-rich diet, and his team has previously shown that equol production is associated with a lower risk of heart disease. As heart disease is strongly associated with cognitive decline and dementia, equol production could help protect the aging brain as well as the heart.


A metabolite produced following consumption of dietary soy may decrease a key risk factor for dementia—with the help of the right bacteria, according to a new discovery led by researchers at the University of Pittsburgh Graduate School of Public Health.

Their study, published today in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions, reports that elderly Japanese men and women who produce equol—a metabolite of dietary soy created by certain types of gut bacteria—display lower levels of white matter lesions within the brain.

“White matter lesions are significant risk factors for cognitive decline, and all-cause mortality,” said lead author Akira Sekikawa, M.D., Ph.D., associate professor of epidemiology at Pitt Public Health. “We found 50% more white matter lesions in people who cannot produce equol compared to people who can produce it, which is a surprisingly huge effect.”

Have you gotten your genome sequenced yet? How important do you think genetic testing is to planning your own personalized longevity regimen?


We cover the benefits of genetic testing for longevity, and why you should consider getting a DNA test if you want to extend your lifespan.